/BTAX

BTAX Stock - Biostax Corp.

Q: What is the analyst price target for BTAX?

Analyst price target information is not currently available for BTAX.

Q: What is BTAX's market cap?

Market capitalization information is not currently available for BTAX.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BTAX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.73

52W High$0.02

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-1,484,950	$-1,163,493	$-738,169	$-887,030
Net Income	$-2,362,647	$-3,536,076	$3.59M	$1.59M
Net Margin	N/A	N/A	N/A	N/A
EPS	$-0.03	$-0.10	$7.43	$3.44

Company Overview

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.

Visit Website